Abbott Reaches New 52-Week High (ABT)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Abbott Laboratories (NYSE: ABT) hit a new 52-week high Tuesday as it is currently trading at $67.49, above its previous 52-week high of $67.45 with 2.4 million shares traded as of 1:05 p.m. ET. Average volume has been 5.8 million shares over the past 30 days.

Abbott has a market cap of $104.66 billion and is part of the health care sector and drugs industry. Shares are up 18.6% year to date as of the close of trading on Monday.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company has a P/E ratio of 21.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Abbott as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Abbott Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Lam Research: Cramer's Top Takeaways

Lam Research: Cramer's Top Takeaways